| The TOR pathway: a target for cancer therapy MA Bjornsti, PJ Houghton Nature Reviews Cancer 4 (5), 335-348, 2004 | 1715 | 2004 |
| Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin GJ Brunn, CC Hudson, A Sekulic, JM Williams, H Hosoi, PJ Houghton, ... Science 277 (5322), 99-101, 1997 | 1258 | 1997 |
| mTOR and cancer therapy JB Easton, PJ Houghton Oncogene 25 (48), 6436-6446, 2006 | 623 | 2006 |
| Targeting mTOR signaling for cancer therapy S Huang, PJ Houghton Current opinion in pharmacology 3 (4), 371-377, 2003 | 609 | 2003 |
| Establishment of human tumor xenografts in immunodeficient mice CL Morton, PJ Houghton Nature protocols 2 (2), 247-250, 2007 | 604 | 2007 |
| A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity S Khan, X Zhang, D Lv, Q Zhang, Y He, P Zhang, X Liu, D Thummuri, ... Nature medicine 25 (12), 1938-1947, 2019 | 529 | 2019 |
| The pediatric preclinical testing program: description of models and early testing results PJ Houghton, CL Morton, C Tucker, D Payne, E Favours, C Cole, ... Pediatric blood & cancer 49 (7), 928-940, 2007 | 519 | 2007 |
| Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations WT Beck, TM Grogan, CL Willman, C Cordon-Cardo, DM Parham, ... Cancer research 56 (13), 3010-3020, 1996 | 508 | 1996 |
| Irinotecan therapy in adults with recurrent or progressive malignant glioma HS Friedman, WP Petros, AH Friedman, LJ Schaaf, T Kerby, J Lawyer, ... Journal of Clinical Oncology 17 (5), 1516-1516, 1999 | 433 | 1999 |
| Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors PJ Houghton, PJ Cheshire, JD Hallman, L Lutz, HS Friedman, MK Danks, ... Cancer chemotherapy and pharmacology 36 (5), 393-403, 1995 | 433 | 1995 |
| Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro PJ Houghton, GS Germain, FC Harwood, JD Schuetz, CF Stewart, ... Cancer research 64 (7), 2333-2337, 2004 | 431 | 2004 |
| Rapamycins: mechanisms of action and cellular resistance S Huang, MA Bjornsti, PJ Houghton Cancer biology & therapy 2 (3), 222-232, 2003 | 420 | 2003 |
| Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells H Hosoi, MB Dilling, T Shikata, LN Liu, L Shu, RA Ashmun, GS Germain, ... Cancer research 59 (4), 886-894, 1999 | 395 | 1999 |
| A specific chromosomal abnormality in rhabdomyosarcoma EC Douglass, M Valentine, E Etcubanas, D Parham, BL Webber, ... Cytogenetic and Genome Research 45 (3-4), 148-155, 1987 | 385 | 1987 |
| Potentiation of neuroblastoma metastasis by loss of caspase-8 DG Stupack, T Teitz, MD Potter, D Mikolon, PJ Houghton, VJ Kidd, ... Nature 439 (7072), 95-99, 2006 | 352 | 2006 |
| mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1α H Cam, JB Easton, A High, PJ Houghton Molecular cell 40 (4), 509-520, 2010 | 327 | 2010 |
| Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition L Dudkin, MB Dilling, PJ Cheshire, FC Harwood, M Hollingshead, ... Clinical Cancer Research 7 (6), 1758-1764, 2001 | 320 | 2001 |
| Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors OM El-Badry, C Minniti, EC Kohn, PJ Houghton, WH Daughaday, ... Cell Growth Differ 1 (7), 325-31, 1990 | 317 | 1990 |
| RAC1: an emerging therapeutic option for targeting cancer angiogenesis and metastasis HK Bid, RD Roberts, PK Manchanda, PJ Houghton Molecular cancer therapeutics 12 (10), 1925-1934, 2013 | 314 | 2013 |
| Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development JK Peterson, PJ Houghton European journal of cancer 40 (6), 837-844, 2004 | 290 | 2004 |
